|
|||||
|
|
Comparative outcomes of everolimus,temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review |
|
| Authors: | Michael K. Wong Hongbo Yang James E. Signorovitch Xufang Wang Zhimei Liu Nathan S. Liu |
| Affiliation: | 1. Norris Comprehensive Cancer Center, University of Southern CaliforniaLos Angeles, CAUSA;2. Analysis Group Inc.Boston, MAUSA;3. Novartis Pharmaceuticals CorporationFlorham Park, NJUSA |
| Abstract: | |
| Keywords: | Molecular targeted therapy Progression-free survival Renal cell carcinoma Survival |